Phase 1Completed
Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants With Obesity
- Sponsor
- Amgen (Industry)
- Enrolment
- 82 enrolled
- Conditions
- Cardiometabolic Disease
- Interventions
- AMG 513; Placebo; AMG 513; Placebo
- Ages
- adults, older adults
- Registry
- NCT06585462
From the registry
The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.
Primary outcomes
- Number of Participants With Treatment-emergent Adverse Events (TEAE)